Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FluINsure
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
FluINsure is an investigational trivalent, live attenuated intranasal influenza vaccine developed to prevent influenza by inducing mucosal and systemic immunity against three influenza virus strains.[7] It is administered as a nasal spray rather than by injection and is designed to mimic natural infection with attenuated virus, stimulating local IgA and cellular responses in the nasopharynx as well as humoral antibody responses.[7] FluINsure was developed by ID Biomedical (formerly Intellivax International) as part of efforts to improve the convenience and immunogenicity of seasonal influenza vaccination.[7][12]
- Brand names
- FluINsure
Beyond the preview
Go deeper on FluINsure.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FluINsure.